Accretion Nutraveda Boosts Governance with New Internal Auditor and Disclosure Authority

Board Approves Key Governance Hires

Accretion Nutraveda Limited's Board of Directors met on March 26, 2026, to make key governance decisions. The board formally approved M/s. KMV & Co., a firm of Chartered Accountants (Registration No. 139787W), as the company's Internal Auditor. The appointment covers the period from February 4, 2026, to March 31, 2026. In a separate move, the company authorized its Key Managerial Personnel (KMPs) to handle regulatory disclosures, including determining the materiality of events for stock exchange reporting and ensuring timely, accurate compliance.

Strengthening Compliance and Transparency

These appointments are important steps for Accretion Nutraveda, especially as a recently listed company. Appointing an internal auditor signals a commitment to robust internal controls and risk management. Authorizing KMPs to handle disclosures improves communication with regulators and shareholders, fostering transparency and investor confidence. This is crucial for a company in the competitive healthcare and nutraceutical market.

Company Background and Auditor Continuity

Accretion Nutraveda Limited, established in 2021 and becoming a public company in 2025, works as a Contract Development and Manufacturing Organization (CDMO) for Ayurvedic and nutraceutical products. The company recently raised about ₹24.77 crore through an SME IPO in early 2026. Importantly, M/s. KMV & Co. is not new to Accretion Nutraveda; they also served as the Statutory Auditor from FY 2022-2023 to FY 2026-2027. This existing relationship suggests a trusted auditor is now handling both internal and external compliance. Accretion Nutraveda also emphasizes quality certifications like GMP and WHO-GMP for its domestic and international manufacturing.

Impact for Shareholders

Shareholders can anticipate an improved internal audit process, offering more assurance regarding the company's operational efficiency and financial reporting. With KMPs formally authorized, specific individuals will now manage the company's ongoing reporting duties to stock exchanges and regulators. These steps reinforce Accretion Nutraveda's commitment to strong corporate governance as the company expands.

Key Risks to Monitor

As a newly public company, Accretion Nutraveda faces inherent risks in scaling operations and maintaining strict compliance in its manufacturing and business processes. The effectiveness of the internal audit and the timely execution of disclosures by authorized KMPs will be key to maintaining investor confidence.

Comparison with Broader Sector Peers

Direct listed competitors for Accretion Nutraveda's specialized Ayurvedic and nutraceutical CDMO business are rare. However, larger FMCG companies such as Dabur India Ltd. and Emami Ltd. are active in the broader health and wellness sector, often featuring their own Ayurvedic product lines. These established companies typically have well-defined governance structures and compliance mechanisms. Accretion Nutraveda's current steps to appoint an internal auditor and empower KMPs for disclosures align with standard industry practices for companies seeking strong corporate governance. The company's core business, however, remains contract manufacturing, unlike the branded product sales focus of Dabur or Emami.

Looking Ahead: Investor Focus Areas

Investors will likely watch for the initial findings from the new internal auditor, M/s. KMV & Co. The timeliness and effectiveness of regulatory disclosures by authorized KMPs will also be important to monitor. Key developments to track will include any future enhancements to the company's internal control systems or governance policies resulting from the internal audit.